{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T02:26:29Z","timestamp":1792808789686,"version":"4.5.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"vor","delay-in-days":55,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Endocr Disord"],"DOI":"10.1186\/s12902-026-02306-x","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T15:53:13Z","timestamp":1779378793000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Interplay of BRAF and TERT promoter mutations and Ki67 proliferation index in papillary thyroid carcinoma in Central Asians"],"prefix":"10.1186","volume":"26","author":[{"given":"Akbota","family":"Targynova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7315-7725","authenticated-orcid":false,"given":"Zhanna","family":"Mussazhanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrey","family":"Bychkov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirokazu","family":"Kurohama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Askar","family":"Tlegenov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dauren","family":"Adilbay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhanar","family":"Yeleubayeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaure","family":"Dushimova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamila","family":"Akhayeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisayoshi","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Nakashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,21]]},"reference":[{"issue":"9","key":"2306_CR1","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1089\/thy.2015.0101","volume":"25","author":"D De Biase","year":"2015","unstructured":"De Biase D, Gandolfi G, Ragazzi M, Eszlinger M, Sancisi V, Gugnoni M, et al. TERT promoter mutations in papillary thyroid microcarcinomas. Thyroid. 2015;25(9):1013\u20139.","journal-title":"Thyroid"},{"key":"2306_CR2","unstructured":"NCCN clinical practice guidelines in oncology. Thyroid Carcinoma Natl Compr Canc Netw. 2022. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/thyroid.pdf. Accessed 12 Oct 2025."},{"issue":"11","key":"2306_CR3","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1056\/NEJMra1501993","volume":"375","author":"JA Fagin","year":"2016","unstructured":"Fagin JA, Wells SA. Biologic and clinical perspectives on thyroid cancer. N Engl J Med. 2016;375(11):1054\u201367.","journal-title":"N Engl J Med"},{"issue":"12","key":"2306_CR4","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1111\/pin.12737","volume":"68","author":"K Kakudo","year":"2018","unstructured":"Kakudo K, Bychkov A, Bai Y, Li Y, Liu Z, Jung CK. The new 4th edition World Health Organization classification for thyroid tumors, Asian perspectives. Pathol Int. 2018;68(12):641\u201364.","journal-title":"Pathol Int"},{"issue":"3","key":"2306_CR5","doi-asserted-by":"publisher","first-page":"E21","DOI":"10.1097\/SLA.0000000000003580","volume":"271","author":"KN Patel","year":"2020","unstructured":"Patel KN, Yip L, Lubitz CC, Grubbs EG, Miller BS, Shen W, et al. The American association of endocrine surgeons guidelines for the definitive surgical management of thyroid disease in adults. Ann Surg. 2020;271(3):E21\u201393.","journal-title":"Ann Surg"},{"key":"2306_CR6","first-page":"1454","volume":"63","author":"ET Kimura","year":"2003","unstructured":"Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET\/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res. 2003;63:1454\u20137.","journal-title":"Cancer Res"},{"issue":"5","key":"2306_CR7","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.21037\/gs-20-430","volume":"9","author":"FA Rashid","year":"2020","unstructured":"Rashid FA, Munkhdelger J, Fukuoka J, Bychkov A. Prevalence of BRAFV600E mutation in Asian series of papillary thyroid carcinoma-a contemporary systematic review. Gland Surg. 2020;9(5):1878\u2013900.","journal-title":"Gland Surg"},{"issue":"12","key":"2306_CR8","doi-asserted-by":"publisher","first-page":"4559","DOI":"10.1210\/jc.2012-2104","volume":"97","author":"C Li","year":"2012","unstructured":"Li C, Lee KC, Schneider EB, Zeiger MA. BRAF V600E mutation and its association with clinicopathological features of papillary thyroid cancer: a meta-analysis. J Clin Endocrinol Metab. 2012;97(12):4559\u201370.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2306_CR9","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1007\/s00268-013-2223-2","volume":"38","author":"Y Ito","year":"2014","unstructured":"Ito Y, Yoshida H, Kihara M, Kobayashi K, Miya A, Miyauchi A. BRAF(V600E) mutation analysis in papillary thyroid carcinoma: is it useful for all patients? World J Surg. 2014;38(3):679\u201387.","journal-title":"World J Surg"},{"issue":"2","key":"2306_CR10","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1111\/cen.12999","volume":"85","author":"M Bullock","year":"2016","unstructured":"Bullock M, Ren Y, O\u2019Neill C, Gill A, Aniss A, Sywak M, et al. TERT promoter mutations are a major indicator of recurrence and death due to papillary thyroid carcinomas. Clin Endocrinol (Oxf). 2016;85(2):283\u201390.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"14","key":"2306_CR11","doi-asserted-by":"publisher","first-page":"18346","DOI":"10.18632\/oncotarget.7811","volume":"7","author":"L Jin","year":"2016","unstructured":"Jin L, Chen E, Dong S, Cai Y, Zhang X, Zhou Y, et al. BRAF and TERT promoter mutations in the aggressiveness of papillary thyroid carcinoma: a study of 653 patients. Oncotarget. 2016;7(14):18346\u201355.","journal-title":"Oncotarget"},{"issue":"25","key":"2306_CR12","doi-asserted-by":"publisher","first-page":"2718","DOI":"10.1200\/JCO.2014.55.5094","volume":"32","author":"M Xing","year":"2014","unstructured":"Xing M, Liu R, Liu X, Murugan AK, Zhu G, Zeiger MA, et al. BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence. J Clin Oncol. 2014;32(25):2718\u201326.","journal-title":"J Clin Oncol"},{"key":"2306_CR13","doi-asserted-by":"publisher","first-page":"41752","DOI":"10.1038\/srep41752","volume":"7","author":"M Matsuse","year":"2017","unstructured":"Matsuse M, Yabuta T, Saenko V, Hirokawa M, Nishihara E, Suzuki K, et al. TERT promoter mutations and Ki-67 labeling index as a prognostic marker of papillary thyroid carcinomas: Combination of two independent factors. Sci Rep. 2017;7:41752.","journal-title":"Sci Rep"},{"issue":"9","key":"2306_CR14","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1002\/cncr.29934","volume":"122","author":"YS Song","year":"2016","unstructured":"Song YS, Lim JA, Choi H, Won JK, Moon JH, Cho SW, et al. Prognostic effects of TERT promoter mutations are enhanced by coexistence with BRAF or RAS mutations and strengthen the risk prediction by the ATA or TNM staging system in differentiated thyroid cancer patients. Cancer. 2016;122(9):1370\u20139.","journal-title":"Cancer"},{"issue":"9","key":"2306_CR15","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1530\/EC-19-0376","volume":"8","author":"AP Estrada-Fl\u00f3rez","year":"2019","unstructured":"Estrada-Fl\u00f3rez AP, Boh\u00f3rquez ME, V\u00e9lez A, Duque CS, Donado JH, Mateus G, et al. BRAF and TERT mutations in papillary thyroid cancer patients of Latino ancestry. Endocr Connect. 2019;8(9):1310\u20137.","journal-title":"Endocr Connect"},{"key":"2306_CR16","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1210\/en.2019-00315","volume":"160","author":"T Trybek","year":"2019","unstructured":"Trybek T, Walczyk A, Ga \u02db Sior-Perczak D, Pa\u0142yga I, Mikina E, Kowalik A, et al. Impact of BRAF V600E and TERT Promoter Mutations on Response to Therapy in Papillary Thyroid Cancer. Endocrinology. 2019;160:2328\u201338.","journal-title":"Endocrinology"},{"key":"2306_CR17","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.mce.2014.10.019","volume":"399","author":"M Muzza","year":"2015","unstructured":"Muzza M, Colombo C, Rossi S, Tosi D, Cirello V, Perrino M, et al. Telomerase in differentiated thyroid cancer: promoter mutations, expression and localization. Mol Cell Endocrinol. 2015;399:288\u201395.","journal-title":"Mol Cell Endocrinol"},{"issue":"2","key":"2306_CR18","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1001\/jamaoncol.2016.3288","volume":"3","author":"R Liu","year":"2017","unstructured":"Liu R, Bishop J, Zhu G, Zhang T, Ladenson PW, Xing M. Mortality risk stratification by combining BRAF V600E and TERT promoter mutations in papillary thyroid cancer genetic duet of BRAF and TERT promoter mutations in thyroid cancer mortality. JAMA Oncol. 2017;3(2):202\u20138.","journal-title":"JAMA Oncol"},{"issue":"6","key":"2306_CR19","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1007\/s00428-016-2027-5","volume":"469","author":"A Nasirden","year":"2016","unstructured":"Nasirden A, Saito T, Fukumura Y, Hara K, Akaike K, Kurisaki-Arakawa A, et al. In Japanese patients with papillary thyroid carcinoma, TERT promoter mutation is associated with poor prognosis, in contrast to BRAF V600E mutation. Virchows Arch. 2016;469(6):687\u201396.","journal-title":"Virchows Arch"},{"issue":"5","key":"2306_CR20","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1007\/s00428-018-2386-1","volume":"473","author":"M Hysek","year":"2018","unstructured":"Hysek M, Paulsson JO, Wang N, Jatta K, Lindh C, Fuentes-Martinez N, et al. TERT promoter mutational screening as a tool to predict malignant behaviour in follicular thyroid tumours-three examples from the clinical routine. Virchows Arch. 2018;473(5):639\u201343.","journal-title":"Virchows Arch"},{"issue":"19","key":"2306_CR21","doi-asserted-by":"publisher","first-page":"2965","DOI":"10.1002\/cncr.28800","volume":"120","author":"N Wang","year":"2014","unstructured":"Wang N, Liu T, Sofiadis A, Juhlin CC, Zedenius J, H\u00f6\u00f6g A, et al. TERT promoter mutation as an early genetic event activating telomerase in follicular thyroid adenoma (FTA) and atypical FTA. Cancer. 2014;120(19):2965\u201379.","journal-title":"Cancer"},{"issue":"4","key":"2306_CR22","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/pin.12893","volume":"70","author":"T Hirokawa","year":"2020","unstructured":"Hirokawa T, Arimasu Y, Nakazato Y, Chiba T, Fujiwara M, Kamma H. Effect of single-nucleotide polymorphism in TERT promoter on follicular thyroid tumor development. Pathol Int. 2020;70(4):210\u20136.","journal-title":"Pathol Int"},{"issue":"7","key":"2306_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers12071846","volume":"12","author":"A Pestana","year":"2020","unstructured":"Pestana A, Batista R, Celestino R, Canberk S, Sobrinho-Sim\u00f5es M, Soares P. Comprehensive assessment of TERT mRNA expression across a large cohort of benign and malignant thyroid tumours. Cancers. 2020;12(7):1\u201317.","journal-title":"Cancers"},{"issue":"3","key":"2306_CR24","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1002\/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9","volume":"182","author":"T Scholzen","year":"2000","unstructured":"Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol. 2000;182(3):311\u201322.","journal-title":"J Cell Physiol"},{"key":"2306_CR25","unstructured":"International Agency for Research on Cancer. WHO Classification of Tumours Editorial Board. Endocrine and neuroendocrine tumours. 2022 [cited 2023 Sep 22]. https:\/\/tumourclassification.iarc.who.int\/"},{"issue":"12","key":"2306_CR26","doi-asserted-by":"publisher","first-page":"3015","DOI":"10.1007\/s00268-010-0746-3","volume":"34","author":"Y Ito","year":"2010","unstructured":"Ito Y, Miyauchi A, Kakudo K, Hirokawa M, Kobayashi K, Miya A. Prognostic significance of ki-67 labeling index in papillary thyroid carcinoma. World J Surg. 2010;34(12):3015\u201321.","journal-title":"World J Surg"},{"issue":"1","key":"2306_CR27","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1159\/000347148","volume":"2","author":"A Miyauchi","year":"2013","unstructured":"Miyauchi A, Kudo T, Hirokawa M, Ito Y, Kihara M, Higashiyama T, et al. Ki-67 labeling index is a predictor of postoperative persistent disease and cancer growth and a prognostic indicator in papillary thyroid carcinoma. Eur Thyroid J. 2013;2(1):57\u201364.","journal-title":"Eur Thyroid J"},{"key":"2306_CR28","first-page":"13","volume":"11","author":"U Kairov","year":"2022","unstructured":"Kairov U, Molkenov A, Sharip A, Rakhimova S, Seidualy M, Rhie A, et al. Whole-genome sequencing and genomic variant analysis of kazakh individuals. Front Genet. 2022;11:13.","journal-title":"Front Genet"},{"key":"2306_CR29","unstructured":"Vakulchuk R, Gjerde KL, Belikhina T, Apsalikov K. Semipalatinsk nuclear testing: the humanitarian consequences: report prepared for the second conference on humanitarian impact of nuclear weapons in Nayarit, Mexico, 13\u201314 February 2014. 2014;(1). [cited 2025 Oct 4]. https:\/\/nupi.brage.unit.no\/nupi-xmlui\/handle\/11250\/193281"},{"key":"2306_CR30","unstructured":"Synnott M. Environmental effects of nuclear testing at Semipalatinsk. Natl Geogr. 2015."},{"key":"2306_CR31","doi-asserted-by":"crossref","unstructured":"Micklin P, Aladin NV, Plotnikov IS. The aral sea: the devastation and partial rehabilitation of a great lake. Aral Sea Devastation Partial Rehabil Gt Lake. 2014;1\u2013453.","DOI":"10.1007\/978-3-642-02356-9"},{"key":"2306_CR32","doi-asserted-by":"crossref","unstructured":"White KD. Environmental issues in Kazakhstan. Glob Encycl Public Adm Public Policy Gov. 2019;1\u20137.","DOI":"10.1007\/978-3-319-31816-5_3854-1"},{"key":"2306_CR33","doi-asserted-by":"crossref","unstructured":"Otsubo C, Mussazhanova Z, Kurohama H, Shalgimbayeva G, Ueki N, Matsuoka Y, et al. Anew indicator to differentiate thyroid follicular inclusions in cervical lymph nodes frompatients with thyroid cancer. Int J Mol Sci. 2022;24(1).","DOI":"10.3390\/ijms24010490"},{"issue":"3","key":"2306_CR34","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.cell.2014.09.050","volume":"159","author":"N Agrawal","year":"2014","unstructured":"Agrawal N, Akbani R, Aksoy BA, Ally A, Arachchi H, Asa SL, et al. Integrated genomic characterization of papillary thyroid carcinoma. Cell. 2014;159(3):676\u201390.","journal-title":"Cell"},{"issue":"1","key":"2306_CR35","first-page":"183","volume":"17","author":"C Zhou","year":"2019","unstructured":"Zhou C, Li J, Wang Y, Xue S, Zhang Y. Association of BRAF gene and TSHR with cervical lymph node metastasis of papillary thyroid microcarcinoma. Oncol Lett. 2019;17(1):183\u201394.","journal-title":"Oncol Lett"},{"issue":"8","key":"2306_CR36","doi-asserted-by":"publisher","first-page":"2685","DOI":"10.1007\/s00268-020-05521-2","volume":"44","author":"S Enumah","year":"2020","unstructured":"Enumah S, Fingeret A, Parangi S, Dias-Santagata D, Sadow PM, Lubitz CC. BRAFV600E mutation is associated with an increased risk of papillary thyroid cancer recurrence. World J Surg. 2020;44(8):2685\u201391.","journal-title":"World J Surg"},{"issue":"14","key":"2306_CR37","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1001\/jama.2013.3190","volume":"309","author":"MM Xing","year":"2013","unstructured":"Xing MM, Alzahrani AS, Carson KA, Viola D, Elisei R, Bendlova B, et al. Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA. 2013;309(14):1493\u2013501.","journal-title":"JAMA"},{"issue":"6","key":"2306_CR38","doi-asserted-by":"publisher","first-page":"289","DOI":"10.4132\/jptm.2023.10.04","volume":"57","author":"K Kakudo","year":"2023","unstructured":"Kakudo K, Jung CK, Liu Z, Hirokawa M, Bychkov A, Vuong HG, et al. The Asian thyroid working group, from 2017 to 2023. J Pathol Transl Med. 2023;57(6):289\u2013304.","journal-title":"J Pathol Transl Med"},{"key":"2306_CR39","first-page":"1062","volume":"11","author":"Z Mussazhanova","year":"2020","unstructured":"Mussazhanova Z, Rogounovitch TI, Saenko VA, Krykpayeva A, Espenbetova M, Azizov B, et al. The Contribution of Genetic Variants to the Risk of Papillary Thyroid Carcinoma in the Kazakh Population: Study of Common SNPs and Their Clinicopathological Correlations. Front Endocrinol (Lausanne). 2020;11:1062.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"4","key":"2306_CR40","doi-asserted-by":"publisher","first-page":"652","DOI":"10.3803\/EnM.2022.1477","volume":"37","author":"H Yang","year":"2022","unstructured":"Yang H, Park H, Ryu HJ, Heo J, Kim JS, Oh YL, et al. Frequency of TERT promoter mutations in real-world analysis of 2,092 thyroid carcinoma patients. Endocrinol Metab (Seoul Korea). 2022;37(4):652\u201363. \/.","journal-title":"Endocrinol Metab (Seoul Korea)"},{"issue":"4","key":"2306_CR41","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/S2213-8587(14)70225-6","volume":"3","author":"MB Zimmermann","year":"2015","unstructured":"Zimmermann MB, Boelaert K. Iodine deficiency and thyroid disorders. Lancet Diabetes Endocrinol. 2015;3(4):286\u201395.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"2306_CR42","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1210\/jc.2008-2390","volume":"94","author":"H Guan","year":"2009","unstructured":"Guan H, Ji M, Bao R, Yu H, Wang Y, Hou P, et al. Association of high iodine intake with the T1799A BRAF mutation in papillary thyroid cancer. J Clin Endocrinol Metab. 2009;94(5):1612\u20137.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2306_CR43","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/nrc3431","volume":"13","author":"M Xing","year":"2013","unstructured":"Xing M. Molecular pathogenesis and mechanisms of thyroid cancer. Nat Rev Cancer. 2013;13(3):184\u201399.","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"2306_CR44","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1210\/er.2009-0011","volume":"30","author":"MB Zimmermann","year":"2009","unstructured":"Zimmermann MB. Iodine deficiency. Endocr Rev. 2009;30(4):376\u2013408.","journal-title":"Endocr Rev"},{"issue":"9","key":"2306_CR45","doi-asserted-by":"publisher","first-page":"2875","DOI":"10.31557\/APJCP.2019.20.9.2875","volume":"20","author":"N Igissinov","year":"2019","unstructured":"Igissinov N, Kozhakhmetov S, Zhantubetova M, Igissinova G, Bilyalova Z, Akpolatova G, et al. Thyroid cancer in kazakhstan: component analysis of incidence dynamics. Asian Pac J Cancer Prev. 2019;20(9):2875\u201380.","journal-title":"Asian Pac J Cancer Prev"},{"key":"2306_CR46","doi-asserted-by":"crossref","unstructured":"Vuong HG, Altibi AMA, Duong UNP, Hassell L. Prognostic implication of BRAF and TERT promoter mutation combination in papillary thyroid carcinoma\u2014a meta-analysis. Clin Endocrinol (Oxf). 2017;2017;87(5):411\u2013417.","DOI":"10.1111\/cen.13413"},{"issue":"6","key":"2306_CR47","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1530\/ERC-17-0562","volume":"26","author":"YS Song","year":"2019","unstructured":"Song YS, Yoo SK, Kim HH, Jung G, Oh AR, Cha JY, et al. Interaction of BRAF-induced ETS factors with mutant TERT promoter in papillary thyroid cancer. Endocr Relat Cancer. 2019;26(6):629\u201341.","journal-title":"Endocr Relat Cancer"},{"issue":"3","key":"2306_CR48","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1111\/bjd.19297","volume":"184","author":"E Manrique-Silva","year":"2021","unstructured":"Manrique-Silva E, Rachakonda S, Mill\u00e1n-Esteban D, Garc\u00eda-Casado Z, Requena C, Trav\u00e9s V, et al. Clinical, environmental and histological distribution of BRAF, NRAS and TERT promoter mutations among patients with cutaneous melanoma: a retrospective study of 563 patients. Br J Dermatol. 2021;184(3):504\u201313.","journal-title":"Br J Dermatol"},{"key":"2306_CR49","doi-asserted-by":"crossref","unstructured":"Gabler L, L\u00f6tsch D, Kirchhofer D, Van Schoonhoven S, Schmidt HM, Mayr L, et al. TERT expression is susceptible to BRAF and ETS-factor inhibition in BRAFV600E\/TERT promoter double-mutated glioma. Acta Neuropathol Commun. 2019;7(1).","DOI":"10.1186\/s40478-019-0775-6"},{"key":"2306_CR50","doi-asserted-by":"crossref","unstructured":"Lei Y, Zhao X, Feng Y, He D, Hu D, Min Y. The value of ki-67 labeling index in central lymph node metastasis and survival of papillary thyroid carcinoma: evidence from the clinical and molecular analyses. Cancer Control. 2023;30.","DOI":"10.1177\/10732748231155701"},{"issue":"7","key":"2306_CR51","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1007\/s00268-021-06070-y","volume":"45","author":"H Lindfors","year":"2021","unstructured":"Lindfors H, Ihre Lundgren C, Zedenius J, Juhlin CC, Shabo I. The clinical significance of lymph node ratio and ki-67 expression in papillary thyroid cancer. World J Surg. 2021;45(7):2155\u201364.","journal-title":"World J Surg"},{"key":"2306_CR52","doi-asserted-by":"publisher","first-page":"8787","DOI":"10.2147\/CMAR.S265756","volume":"12","author":"X Yao","year":"2020","unstructured":"Yao X, Meng Y, Guo R, Lu G, Jin L, Wang Y, et al. Value of ultrasound combined with immunohistochemistry evaluation of central lymph node metastasis for the prognosis of papillary thyroid carcinoma. Cancer Manag Res. 2020;12:8787\u201399.","journal-title":"Cancer Manag Res"}],"container-title":["BMC Endocrine Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12902-026-02306-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-026-02306-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-026-02306-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T04:39:48Z","timestamp":1784090388000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12902-026-02306-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,21]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2306"],"URL":"https:\/\/doi.org\/10.1186\/s12902-026-02306-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6904653\/v1","asserted-by":"object"}]},"ISSN":["1472-6823"],"issn-type":[{"value":"1472-6823","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,21]]},"assertion":[{"value":"16 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Studies involving human participants were reviewed and approved by the Al-Farabi Kazakh National University in Kazakhstan and the Nagasaki University Human Genome Ethics Committee in Japan, and were conducted in accordance with the Declaration of Helsinki. Written informed consent to participate in this study was obtained from all participants or, when applicable, from their legal guardians or next of kin.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"206"}}